Raising the Index of Suspicion in Primary Care: The Role of the Nurse Practitioner in Recognizing and Managing Diabetic Kidney Disease

Raising the Index of Suspicion in Primary Care: The Role of the Nurse Practitioner in Recognizing and Managing Diabetic Kidney Disease is organized by Integrity Continuing Education Inc..,Release date: 29- 06- 2022,Expiration date: 29- 06- 2023,Program Overview:,Treatment for diabetic kidney disease has undergone a recent evolution with the approval and guideline recommendations of newer therapies for treatment, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and recently, non-steroidal selective mineralocorticoid receptor antagonists (MRAs). These therapies have the potential to reduce cardiovascular disease (CVD) risk and DKD progression. As newer agents begin to take their place in practice and to further reduce renal risk in patients with diabetes, clinicians need to become aware of these therapies, their mechanism of action, and best practices for their use so they can integrate them into care of patients with DKD. This educational activity will also address recommended strategies to screen for and ensure an early diagnosis of DKD and discuss the impact of inflammation and fibrosis on CV risk. The goal of the activity is optimization of care of patients with or at risk for development of DKD.,Learning Objectives:,Upon completion of this educational activity, participants should be able to:,• List recommended screening strategies to ensure early diagnosis of chronic kidney disease (CKD) in patients with diabetes, including the use of urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR),• Discuss how DKD confers a high risk of CVD, renal events, and associated mortality, and DKD’s implications for patient management,• Describe the role of inflammation, fibrosis, and the mineralocorticoid receptor in the progression of DKD,• Describe how to incorporate current treatment approaches and discuss novel treatment approaches based on current and emerging data, to optimize the care of patients with type 2 diabetes and decrease the risk of progression of DKD,Additional details will be posted as soon as information is available.